424 related articles for article (PubMed ID: 32744334)
21. Use of echinocandin prophylaxis in solid organ transplantation.
Giannella M; Husain S; Saliba F; Viale P
J Antimicrob Chemother; 2018 Jan; 73(suppl_1):i51-i59. PubMed ID: 29304212
[TBL] [Abstract][Full Text] [Related]
22. Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.
Gatti M; Rinaldi M; Ferraro G; Toschi A; Caroccia N; Arbizzani F; Raschi E; Poluzzi E; Pea F; Viale P; Giannella M
Mycoses; 2021 Nov; 64(11):1317-1327. PubMed ID: 34387004
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis, pre-emptive or empirical antifungal therapy: which is best in non-lung transplant recipients?
Salavert M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S149-53. PubMed ID: 19013340
[TBL] [Abstract][Full Text] [Related]
24. Management of invasive fungal infections: a role for polyenes.
Chandrasekar P
J Antimicrob Chemother; 2011 Mar; 66(3):457-65. PubMed ID: 21172787
[TBL] [Abstract][Full Text] [Related]
25. Emerging fungal infections in solid organ transplant recipients.
Shoham S
Infect Dis Clin North Am; 2013 Jun; 27(2):305-16. PubMed ID: 23714342
[TBL] [Abstract][Full Text] [Related]
26. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
[TBL] [Abstract][Full Text] [Related]
27. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies.
Cornely OA; Ullmann AJ; Karthaus M
Blood; 2003 May; 101(9):3365-72. PubMed ID: 12393455
[TBL] [Abstract][Full Text] [Related]
28. Complications of invasive mycoses in organ transplant recipients.
Samanta P; Singh N
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1195-1202. PubMed ID: 27690694
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients.
Neofytos D; Fishman JA; Horn D; Anaissie E; Chang CH; Olyaei A; Pfaller M; Steinbach WJ; Webster KM; Marr KA
Transpl Infect Dis; 2010 Jun; 12(3):220-9. PubMed ID: 20113459
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
Wong TY; Loo YS; Veettil SK; Wong PS; Divya G; Ching SM; Menon RK
Sci Rep; 2020 Sep; 10(1):14575. PubMed ID: 32884060
[TBL] [Abstract][Full Text] [Related]
31. Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital.
Camplesi M; Silva HM; Arantes AM; Costa CR; Ataides FS; Silva TC; Reis MP; Silva MD
Rev Soc Bras Med Trop; 2017; 50(1):80-85. PubMed ID: 28327806
[TBL] [Abstract][Full Text] [Related]
32. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.
Baker AW; Maziarz EK; Arnold CJ; Johnson MD; Workman AD; Reynolds JM; Perfect JR; Alexander BD
Clin Infect Dis; 2020 Jan; 70(1):30-39. PubMed ID: 30801642
[TBL] [Abstract][Full Text] [Related]
33. The role of primary antifungal prophylaxis in patients with haematological malignancies.
Pagano L; Caira M
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
36. Invasive mould infections in the ICU setting: complexities and solutions.
Bassetti M; Bouza E
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i39-i47. PubMed ID: 28355466
[TBL] [Abstract][Full Text] [Related]
37. [Fungal infections in children with malignant disease].
Michel G
Arch Pediatr; 2011 May; 18 Suppl 1():S3-7. PubMed ID: 21596284
[TBL] [Abstract][Full Text] [Related]
38. [Indications for surgical management of visceral fungal infections].
Pilmis B; Lortholary O; Lanternier F
Rev Prat; 2015 Dec; 65(10):1340-2. PubMed ID: 26979040
[No Abstract] [Full Text] [Related]
39. Frequency and Determinants of Invasive Fungal Infections in Children With Solid and Hematologic Malignancies in a Nonallogeneic Stem Cell Transplantation Setting: A Narrative Review.
Ruijters VJ; Oosterom N; Wolfs TFW; van den Heuvel-Eibrink MM; van Grotel M
J Pediatr Hematol Oncol; 2019 Jul; 41(5):345-354. PubMed ID: 30973485
[TBL] [Abstract][Full Text] [Related]
40. [Current status of invasive fungal infections. New diagnostic techniques and antifungal agents].
Gurguí M; Cuenca-Estrella M
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():1-6. PubMed ID: 19572428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
